Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Latest
Popular

PIK3CA mutation predicts resistance to anti-HER2 treatment and chemotherapy

Dr Sibylle Loibl - German Breast Cancer Group
PIK3CA mutation predicts resistance to anti-HER2 treatment and chemotherapy ( Dr Sibylle Loibl - German Breast Cancer Group )
19 Dec 2013

Where to next for the elderly with acute myeloid leukaemia?

Dr Uwe Platzbecker - University Hospital Dresden, Germany and Prof Gert Ossenkoppele - VU University Medical Center, Amsterdam, Netherlands
Where to next for the elderly with acute myeloid leukaemia? ( Dr Uwe Platzbecker - University Hospital Dresden, Germany and Prof Gert Ossenkoppele - VU University Medical Center, Amsterdam, Netherlands )
19 Dec 2013

Novel agent CC-292 for CLL using the B-cell receptor pathway

Dr Jennifer Brown - Dana-Farber Cancer Institute, Boston, USA
Novel agent CC-292 for CLL using the B-cell receptor pathway ( Dr Jennifer Brown - Dana-Farber Cancer Institute, Boston, USA )
18 Dec 2013

Encouraging early results with GS-9973 for CLL and NHL

Dr Jeff Sharman- US Oncology, Eugene, Oregon
Encouraging early results with GS-9973 for CLL and NHL ( Dr Jeff Sharman- US Oncology, Eugene, Oregon )
18 Dec 2013

PI3K-delta inhibitor idelalisib success in CLL

Dr Jennifer Brown - Dana-Farber Cancer Institute, Boston, USA
PI3K-delta inhibitor idelalisib success in CLL ( Dr Jennifer Brown - Dana-Farber Cancer Institute, Boston, USA )
18 Dec 2013

Benefit of lenalidomide and low-dose dexamethasone over standard therapy for multiple myeloma

Dr Thierry Facon - Centre Hospitalier Régional Universitaire de Lille, Lille, France
Benefit of lenalidomide and low-dose dexamethasone over standard therapy for multiple myeloma ( Dr Thierry Facon - Centre Hospitalier Régional Universitaire de Lille, Lille, France )
18 Dec 2013

T cell immunotherapy for leukaemia in preclinical setting

Dr Michael Kalos - University of Pennsylvania, Philadelphia, USA
T cell immunotherapy for leukaemia in preclinical setting ( Dr Michael Kalos - University of Pennsylvania, Philadelphia, USA )
17 Dec 2013

Idelalisib and rituximab for previously treated chronic lymphocytic leukaemia (CLL)

Dr Richard Furman - New York Weill Cornell Medical Center, USA
Idelalisib and rituximab for previously treated chronic lymphocytic leukaemia (CLL) ( Dr Richard Furman - New York Weill Cornell Medical Center, USA )
17 Dec 2013

New agents in CLL

Dr Jacqueline Barrientos - LIJ Medical Center, New York, USA
New agents in CLL ( Dr Jacqueline Barrientos - LIJ Medical Center, New York, USA )
13 Dec 2013

Chronic lymphocytic leukaemia: A new treatment era is born

Dr John Gribben - Barts Cancer Institute, London, UK
Chronic lymphocytic leukaemia: A new treatment era is born ( Dr John Gribben - Barts Cancer Institute, London, UK )
13 Dec 2013

Lenalidomide promotes CRBN-mediated ubiquitination and degradation of IKZF1 and IKZF3

Dr Jan Krönke - Brigham and Women's Hospital, Boston, USA
Lenalidomide promotes CRBN-mediated ubiquitination and degradation of IKZF1 and IKZF3 ( Dr Jan Krönke - Brigham and Women's Hospital, Boston, USA )
8 Dec 2013

Final stage II results of the CLL11 trial

Dr Valentin Goede - University of Cologne, Germany
Final stage II results of the CLL11 trial ( Dr Valentin Goede - University of Cologne, Germany )
8 Dec 2013

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation